Latest news with #AbCellera
National Post
3 days ago
- Business
- National Post
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. Article content 'In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our transition to a clinical-stage biotechnology company,' said Carl Hansen, Ph.D., founder and CEO of AbCellera. 'Today we also announced that a third program, ABCL688, has advanced into IND-enabling studies. With over $750 million in available liquidity, we are well-positioned to continue to execute our strategy.' Article content Q2 2025 Business Summary Article content Generated a net loss of $34.7 million, compared to a net loss of $36.9 million in 2024. Received authorization from Health Canada to initiate Phase 1 clinical trials for ABCL635 and ABCL575, bringing the cumulative total of molecules to reach the clinic to 18. Advanced ABCL688, an ion channel- or GPCR-targeted antibody development candidate (autoimmunity), into IND/CTA-enabling studies. Presented preclinical data for ABCL575 at the Society for Investigative Dermatology. Reached a cumulative total of 102 partner-initiated program starts with downstreams. Article content Recent Developments Article content ABCL635 (Endocrinology/Women's Health): AbCellera has initiated dosing of participants in a Phase 1 clinical trial of ABCL635, a potential non-hormonal, long-acting treatment for moderate-to-severe VMS, commonly known as hot flashes, associated with menopause. This is a randomized, placebo-controlled, double-blind Phase 1 study in healthy men and postmenopausal women with or without VMS. Its purpose is to evaluate safety, pharmacokinetics, pharmacodynamics, as well as frequency and severity of VMS with subcutaneous doses of ABCL635. The initial safety and efficacy data from this study is expected to be presented in mid 2026. ABCL575 (Immunology and Inflammation): AbCellera has initiated a Phase 1 clinical trial of ABCL575, which is being developed for the treatment of moderate-to-severe atopic dermatitis. This is a randomized, placebo-controlled, double-blind study to assess safety and tolerability in healthy participants following subcutaneous doses of ABCL575. ABCL575 is an OX40-ligand-targeting antibody engineered to support a dosing interval of once every 6 months. Article content AbCellera started discovery on an additional five partner-initiated programs with downstreams to reach a cumulative total of 102 partner-initiated program starts with downstreams in Q2 2025 (up from 93 on June 30, 2024). AbCellera and its partners have advanced a cumulative total of 18 molecules into the clinic (up from 14 on June 30, 2024). Article content Discussion of Q2 2025 Financial Results Article content Revenue – Total revenue was $17.1 million, compared to $7.3 million in Q2 2024. Research & Development (R&D) Expenses – R&D expenses were $39.2 million, compared to $40.9 million in Q2 2024. A greater proportion of R&D expenses are used on internal programs reflecting the increased emphasis on building the internal pipeline. Sales & Marketing (S&M) Expenses – S&M expenses were $3.0 million, compared to $3.1 million in Q2 2024. General & Administrative (G&A) Expenses – G&A expenses were $19.0 million, compared to $20.2 million in Q2 2024. Net Loss – Net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, compared to net loss of $36.9 million, or $(0.13) per share on a basic and diluted basis, in Q2 2024. Liquidity – $580 million of total cash, cash equivalents, and marketable securities and approximately $173 million in available non-dilutive government funding, bringing total available liquidity to approximately $753 million to execute on AbCellera's strategy. Article content Conference Call and Webcast Article content AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Article content The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera's Investor Relations website. A replay of the webcast will be available through the same link following the conference call. Article content About AbCellera Biologics Inc Article content . Article content AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit Article content Definition of Key Business Metrics Article content We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections, and make strategic decisions. We believe that the following metrics are important to understand our current business. These metrics may change or may be substituted for additional or different metrics as our business develops. Article content Partner-initiated program starts with downstreams Article content represent the number of unique partner-initiated programs where we stand to participate financially in downstream success for which we have commenced the discovery effort. The discovery effort commences on the later of (i) the day on which we receive sufficient reagents to start discovery of antibodies against a target and (ii) the day on which the kick-off meeting for the program is held. We view this metric as an indication of the selection and initiation of projects by our partners and the resulting potential for near-term payments. Cumulatively, partner-initiated program starts with downstream participation indicate our total opportunities to earn downstream revenue from milestone fees and royalties (or royalty equivalents) in the mid- to long-term. Article content Molecules in the clinic Article content represent the count of unique molecules for which an Investigational New Drug, or IND, New Animal Drug, or equivalent under other regulatory regimes, application has reached 'open' status or has otherwise been approved based on an antibody that was discovered either by us or by a partner using licensed AbCellera technology. Where the date of such application approval is not known to us, the date of the first public announcement of a clinical trial will be used for the purpose of this metric. We view this metric as an indication of our near- and mid-term potential revenue from milestone fees and potential royalty payments in the long term. Article content AbCellera Forward-Looking Statements Article content This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Article content In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under 'Risk Factors,' 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. Article content Three months ended June 30, Six months ended June 30, 2024 2025 2024 2025 Revenue: Research fees $ 5,453 $ 6,639 $ 15,227 $ 10,707 Licensing revenue 370 10,445 550 10,613 Milestone payments 1,500 – 1,500 – Total revenue 7,323 17,084 17,277 21,320 Operating expenses: Research and development (1) 40,927 39,213 80,214 81,711 Sales and marketing (1) 3,136 3,009 6,501 5,851 General and administrative (1) 20,192 18,977 37,544 35,203 Depreciation, amortization, and impairment 36,522 5,470 41,366 10,801 Total operating expenses 100,777 66,669 165,625 133,566 Loss from operations (93,454 ) (49,585 ) (148,348 ) (112,246 ) Other (income) expense: Interest income (9,801 ) (7,592 ) (20,202 ) (15,643 ) Grants and incentives (3,310 ) (3,692 ) (6,585 ) (7,845 ) Other (32,156 ) (1,957 ) (30,627 ) 570 Total other income (45,267 ) (13,241 ) (57,414 ) (22,918 ) Net loss before income tax (48,187 ) (36,344 ) (90,934 ) (89,328 ) Income tax recovery (11,257 ) (1,617 ) (13,394 ) (8,980 ) Net loss $ (36,930 ) (34,727 ) $ (77,540 ) $ (80,348 ) Foreign currency translation adjustment (257 ) 4,341 (353 ) 1,721 Comprehensive loss $ (37,187 ) $ (30,386 ) $ (77,893 ) $ (78,627 ) Net loss per share Basic $ (0.13 ) $ (0.12 ) $ (0.26 ) $ (0.27 ) Diluted $ (0.13 ) $ (0.12 ) $ (0.26 ) $ (0.27 ) Weighted-average common shares outstanding Article content Article content Article content Article content Article content Contacts Article content Inquiries Article content Media: Tiffany Chiu; Article content media@ Article content , +1(236)521-6774 Article content Article content Partnering: Murray McCutcheon, Ph.D.; Article content Article content Article content
Yahoo
22-07-2025
- Business
- Yahoo
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot
AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the top high-return penny stocks to buy now. On July 7, Leerink Partners resumed coverage of the stock with an 'Outperform' rating and a $5 price target. The research firm remains confident about the company's long-term prospects following its pivot from an antibody discovery platform to one that develops its internal pipeline. A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company. Leerink Partners is especially bullish about the company's upcoming programs ABCL575, an OX40L antagonist targeting atopic dermatitis, and ABCL635, an NK3R antagonist for vasomotor symptoms. The two programs are scheduled to enter Phase 1 clinical trials in the third quarter of 2025. The research firm also pointed out that AbCellera's existing antibody discovery collaborations are well-positioned to deliver long-term value. It expects the company to benefit from milestone payments and royalties as it leverages antibody capabilities towards a pipeline focused on validated targets. AbCellera Biologics Inc. (NASDAQ:ABCL) is a biotechnology company that focuses on discovering and developing antibody-based medicines. It leverages a proprietary, AI-powered technology platform to search, decode, and analyze natural immune systems, identifying antibodies that can be developed into potential drugs. While we acknowledge the potential of ABCL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-07-2025
- Business
- Yahoo
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
VANCOUVER, British Columbia, July 07, 2025--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit View source version on Contacts Inquiries Media: Tiffany Chiu; media@ +1(236)521-6774Partnering: Murray McCutcheon, Ph.D.; bd@ +1(604)559-9005Investor Relations: Peter Ahn; ir@ +1(778)729-9116 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
National Post
07-07-2025
- Business
- National Post
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
Article content VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. Article content A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. Article content About AbCellera Biologics Inc. Article content AbCellera Article content (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit Article content Article content Article content Article content Article content Contacts Article content Inquiries Article content Article content Media: Tiffany Chiu; Article content media@ Article content , +1(236)521-6774 Article content Article content Partnering: Murray McCutcheon, Ph.D.; Article content Article content Article content
Business Wire
07-07-2025
- Business
- Business Wire
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit
